Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 2Prostatic Neoplasms 1Neoplasms 1Brain Neoplasms 1

Interventions

Radiosurgery 23Radiotherapy 20Temozolomide 17Lomustine 9Bevacizumab 8Surgical Procedures, Operative 7Procarbazine 6Vincristine 5Nivolumab 5Memantine 5Magnetic Resonance Spectroscopy 4Filgrastim 4Etoposide 4Cisplatin 4Carboplatin 4Specimen Handling 3Sodium Chloride 3Radiation 3Methylphenidate 3Mental Status and Dementia Tests 3Granulocyte Colony-Stimulating Factor 3Gefitinib 3Cyclophosphamide 3Corticotropin-Releasing Hormone 3Carmustine 3icotinib 2etoposide phosphate 2efaproxiral 2X-Rays 2Tranexamic Acid 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Brain Neoplasms × gadobutrol × Clear all
NCT00522951 2017-08-28

SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study

Bayer

Phase 3 Completed
165 enrolled 24 charts
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡